文献速递骨软组织肉瘤与黑色素瘤

辅助免疫治疗在真实世界全国性黑色素瘤队列中的结局

Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
PubMed 文献 · Eur J Cancer · 2024-03-19

这项基于丹麦转移性黑色素瘤数据库(DAMMED)的观察性人群研究,纳入2018年11月至2022年1月接受辅助抗PD-1治疗的785例已切除III-IV期黑色素瘤患者,中位随访25.6个月(95%CI 24-28)。1年、2年、3年无复发生存率分别为78%、66%、59%,黑色素瘤特异性生存率分别为97%、93%、87%,与随机对照试验结果一致;因非复发原因提前停药者与完成计划治疗者结局相似。

要点

  • 真实世界辅助抗PD-1的1年、2年、3年无复发生存率分别为78%、66%、59%。
  • 1年、2年、3年黑色素瘤特异性生存率分别为97%、93%、87%。
  • 42%完成计划治疗,32%因毒性停药,19%因复发停药。

核心结论

  • 真实世界中接受辅助抗PD-1治疗的黑色素瘤患者生存结局与随机对照试验结果一致。
  • 因非复发原因提前停药的患者与完成计划治疗的患者结局相似。
  • 辅助抗PD-1后一线转移治疗中,伊匹木单抗联合纳武利尤单抗相比伊匹木单抗单药未改善结局。

研究设计与样本

  • 观察性人群研究,基于丹麦转移性黑色素瘤数据库(DAMMED)全国队列。
  • 纳入2018年11月至2022年1月转诊接受辅助治疗的已切除III-IV期黑色素瘤患者785例,均接受辅助抗PD-1治疗。
  • 87%为III期已切除黑色素瘤,80%乳酸脱氢酶水平正常,87%体能评分为0。
  • 中位随访25.6个月(95%CI 24-28)。

主要发现

  • 中位无复发生存期(RFS)和黑色素瘤特异性生存期(MSS)均未达到。
  • 1年、2年、3年RFS分别为78%(95%CI 75-81)、66%(95%CI 63-70)、59%(95%CI 55-63)。
  • 1年、2年、3年MSS分别为97%(95%CI 95-98)、93%(95%CI 91-95)、87%(95%CI 84-90)。
  • 42%完成计划治疗,32%因毒性停药,19%因黑色素瘤复发停药。
  • 多变量分析中,辅助抗PD-1后一线转移治疗采用伊匹木单抗联合纳武利尤单抗相比伊匹木单抗单药未改善结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions. METHODS: Observational population-based study examining a national cohort of patients with resected stage III-IV melanoma referred for adjuvant therapy. Data were extracted from the Danish Metastatic Melanoma Database (DAMMED). RESULTS: Between November 2018 and January 2022, 785 patients received adjuvant anti-PD-1. The majority had stage III resected melanoma (87%), normal LDH levels (80%), and performance score 0 (87%). Patients were followed for a median of 25.6 months (95%CI 24-28). The median recurrence-free survival (RFS) and melanoma-specific survival (MSS) were not reached. The RFS was 78% (95%CI 75-81), 66% (63-70), and 59% (55-63); MSS was 97% (95-98), 93% (91-95), and 87% (84-90) at 1-, 2-, and 3-year; respectively. Less than half (42%) of the patients finalized planned therapy, 32% discontinued due to toxicity, and 19% due to melanoma recurrence. Patients discontinuing adjuvant treatment prematurely, without recurrence, had similar outcomes as patients finalizing therapy. In a multivariable analysis, ipilimumab plus nivolumab did not improve outcomes compared to ipilimumab monotherapy as a first-line metastatic treatment after adjuvant anti-PD-1. CONCLUSION: Survival outcomes in real-world patients with melanoma treated with adjuvant anti-PD-1 align with results from the randomized controlled trials. Patients discontinuing therapy prematurely, for other reasons than recurrence, had similar outcomes as patients finalizing planned treatment. First-line metastatic treatment with ipilimumab and nivolumab post-adjuvant anti-PD-1 did not show improved outcomes compared to ipilimumab/anti-PD-1 monotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Holmstroem RB, Pedersen S, Jurlander R, et al. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma. Eur J Cancer. 2024. PMID: 38518533. doi:10.1016/j.ejca.2024.114023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。